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18F-FDG PET/CT is used in a variety of cancers, but because of
variable rates of glucose metabolism, not all cancers are reliably
identified. 18F2 PET/CT allows for the acquisition of highly sen-
sitive and specific images of the skeleton. We prospectively
evaluated combined 18F2/18F-FDG as a single PET/CT exami-
nation for evaluation of cancer patients and compared it with
separate 18F2 PET/CT and 18F-FDG PET/CT scans. Methods:
One hundred fifteen participants with cancer were prospec-
tively enrolled in an international multicenter trial evaluating
18F2 PET/CT, 18F-FDG PET/CT, and combined 18F2/18F-FDG
PET/CT. The 3 PET/CT scans were performed sequentially
within 4 wk of one another for each patient. Results: 18F2/18F-
FDG PET/CT allowed for accurate interpretation of radiotracer
uptake outside the skeleton, with findings similar to those of
18F-FDG PET/CT. In 19 participants, skeletal disease was more
extensive on 18F2 PET/CT and 18F2/18F-FDG PET/CT than on
18F-FDG PET/CT. In another 29 participants, 18F2 PET/CT and
18F2/18F-FDG PET/CT showed osseous metastases where 18F-
FDG PET/CT was negative. The extent of skeletal lesions was
similar in 18 participants on all 3 scans. Conclusion: This trial
demonstrated that combined 18F2/18F-FDG PET/CT shows
promising results when compared with separate 18F2 PET/CT
and 18F-FDG PET/CT for evaluation of cancer patients. This
result opens the possibility for improved patient care and re-
duction in health-care costs, as will be further evaluated in
future trials.
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PET and PET/CT performed with 18F-FDG is used in
a variety of cancers, for which it has changed the practice
of oncology (1). However, because of variable rates of
glucose metabolism, not all malignant lesions are reliably
identified, contributing to the overall limitations of this
method (2). The initial staging of patients diagnosed with
certain cancers includes imaging with 18F-FDG PET/CT
and 99mTc-methylenediphosphonate (99mTc-MDP) bone
scintigraphy as separate studies (3,4). 99mTc-MDP bone
scintigraphy is the method of choice for evaluation of os-
seous metastases, since it allows a whole-body survey at
a relatively low cost. Before the introduction of 99mTc-
based agents, bone scintigraphy with sodium fluoride-18
(18F2) was performed using g-cameras, despite the fact that
511-keV photons are suboptimal for conventional nuclear
medicine scanners (5). 18F2 is a positron emitter; therefore,
imaging the skeleton with 18F-NaF PET/CT allows for the
acquisition of highly sensitive and specific images (6).
High-quality images of the skeleton can be obtained start-
ing less than 1 h after the intravenous administration of
18F2(7). The Society of Nuclear Medicine and Molecular
Imaging published practice guidelines for 18F2 PET/CT
(8), and the Centers for Medicare and Medicaid Services
approved reimbursement of 18F2 PET/CT when performed
through the National Oncologic PET Registry.
After completing a pilot study on 14 participants (9), we
reported the feasibility of combining 18F2 and 18F-FDG in
a single PET/CT scan for cancer detection. We now present
the results of a prospective international multicenter study
that further investigated combined 18F2/18F-FDG PET/CT
for evaluation of the extent of malignancy.
MATERIALS AND METHODS
The Institutional Review Boards of the 4 participating institu-
tions (Aalborg University [Denmark], Coimbra University [Portu-
gal], Pretoria University [South Africa], and Stanford University
[United States]) approved this study. One hundred fifteen consec-
utive participants (including 14 from the pilot study) were
recruited prospectively from November 2007 to July 2012. All
participants (63 men and 52 women; age range, 19–84 y; average
age 6 SD, 58.5 6 14.3 y) gave written informed consent before
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enrollment in the trial. All cancer types were included in the study
in order to simulate actual clinical experience. Seventeen percent
of the participants were referred to determine the initial treatment
strategy (formerly diagnosis and initial staging), whereas 83% of
the patients were referred for determining a subsequent treatment
strategy (including treatment monitoring, restaging, and detection
of suspected recurrence). This classification is based on the Na-
tional Coverage Determination for 18F-FDG PET for Oncologic
Conditions from the Centers for Medicare and Medicaid Services
(10). The diagnoses included prostate cancer (41 participants),
breast cancer (39 participants), sarcoma (22 participants), and other
cancers (13 participants). The participants’ clinical data are sum-
marized in Tables 1 and 2. All participants underwent 18F2 PET/CT,
18F-FDG PET/CT, and combined 18F2/18F-FDG PET/CT. The in-
terval between the first and third scans ranged from 3 to 28 d (average,
6.7 6 4.9 d).
PET/CT Protocols and Image Reconstruction
Whole-body images were obtained using the following PET/CT
scanners: Discovery LS 600 and 690 (GE Healthcare; Stanford),
Discovery VCT (GE Healthcare; Aalborg), Discovery ST (GE
Healthcare; Coimbra), and Biograph 40 (Siemens; Pretoria). The
patients fasted at least 6 h before the 18F-FDG scans (separate or
combined), and blood glucose levels were less than 150 mg/dL at
the time of the 18F-FDG injection. Approximately 60 min after
intravenous administration of the radiopharmaceutical, a multislice
helical noncontrast CT scan was obtained from the skull vertex to
the toes. This scan was used for attenuation correction and ana-
tomic localization of the administered radiopharmaceuticals. Im-
mediately after the CT scan, an emission PET scan was acquired
over the same anatomic regions. The PET images were corrected
using segmented attenuation data from the CT scan. PET images
were reconstructed with a standard iterative algorithm; reformat-
ted into axial, coronal, and sagittal views; and reviewed centrally
(Stanford). The prescribed doses were 370–555 MBq (10–15 mCi)
for 18F-FDG, 185–370 MBq (5–10 mCi) for 18F2, and 555 MBq
(15 mCi) of 18F-FDG 1 185 MBq (5 mCi) of 18F2 for the com-
bined scan. For the 18F2/18F-FDG scans, the 2 radiotracers were
delivered from the local cyclotron facilities in separate syringes
and administered sequentially, with less than a minute delay. The
order of administration was not controlled.
Image Analysis
The 18F2 PET/CT, 18F-FDG PET/CT, and 18F2/18F-FDG PET/CT
images were interpreted in randomized order by 2 board-certified
nuclear medicine physicians unaware of the diagnosis and the results
of other imaging studies, using the software provided by the manu-
facturer (Xeleris; GE Healthcare). The readers were masked to the 2
other scans when reading 1 scan in a given patient in order to avoid
recall bias. Discrepancies were resolved by a consensus reading. A
direct comparison for each detected lesion was performed among
the 3 scans. For image interpretation, visual analysis was used
instead of quantitative analysis. For 18F2 PET/CT, areas of fo-
cally increased 18F2 skeletal uptake were read as malignant un-
less a benign etiology for this uptake was identified at the same
location on the corresponding CT images. For 18F-FDG PET/CT,
focal 18F-FDG uptake less than that of the mediastinal blood
pool was considered benign, uptake equal to that of the medias-
tinal blood pool was considered uncertain, and uptake greater
than that of the mediastinal blood pool was considered malig-
nant. Prior work has shown the validity of qualitative assessment
of 18F-FDG uptake in various malignancies (11–15). For the
18F2/18F-FDG PET/CT scans, the above-mentioned criteria were
combined to define focal uptake as benign, uncertain, or malignant.
In the subgroup of participants with more skeletal lesions
detected on 18F2 PET/CT and combined 18F2/18F-FDG PET/CT
than on 18F-FDG PET/CT, CT images of the bones were also
evaluated independently by 2 board-certified radiologists masked
to the diagnosis and the results of the PET scanning. Discrepancies
were resolved by a consensus reading.
Each patient had all 3 scans acquired on the same scanner to
avoid variability. Phantom studies were not conducted to
calibrate the scanners used at the 4 participating institutions.
However, because no quantitative or semiquantitative analyses
were used, lack of calibration did not interfere with the results of
the study.
RESULTS
The injected doses of 18F-FDG ranged from 358.9 to 684.5
(9.7–18.5 mCi) (average, 503.26 92.5 MBq [13.66 2.5 mCi])
for the separate scans and from 162.8 to 662.3 MBq (4.4–17.9
mCi) (average, 444 6 88.8 MBq [12.0 6 2.4 mCi]) for the
combined scans (P 5 0.0007). The injected doses of 18F2
ranged from 144.3 to 503.2 MBq (3.9–13.6 mCi) (average,
251.6 6 96.2 MBq [6.8 6 2.6 mCi]) for the separate scans
and from 136.9 to 518 MBq (3.7–14 mCi) (average, 196.1 6
51.8 MBq [5.3 6 1.4 mCi]) for the combined scans (P 5
0.0001). The time from intravenous administration of the radio-
pharmaceuticals to imaging ranged from 43 to 157 min (aver-
age, 81.1 6 20.2) for the separate 18F-FDG scans, from 39 to
154 min (average, 84.56 23.7) for the separate 18F2 scans, and
from 52 to 213 min (average, 86.0 6 26.5) for the combined
scans. These time differences were not statistically significant.
The variations in doses and times from injection to imag-
TABLE 1
Clinical Data of Patient Population Included in This Study
Characteristic Male Female
N 63 52






Initial treatment strategy 10 9










Non-Hodgkin lymphoma 1 0
Larynx 0 1
Paraganglioma 1 0
COMBINED 18F-FLUORIDE AND 18F-FDG PET/CT • Iagaru et al. 177
by on April 22, 2016. For personal use only. jnm.snmjournals.org Downloaded from 
ing are part of routine clinical practice even at major
academic centers (16).
For the 96 patients referred for imaging as part of the
subsequent treatment strategy, the time from the most recent
treatment to the first scan done as part of the research
protocol ranged from 1.5 to 204 mo (average, 44.4 mo).
Combining the findings of the separate 18F2 PET/CT and
18F-FDG PET/CT scans resulted in identification of malig-
nant lesions in 82 of the 115 participants. One patient di-
agnosed with prostate cancer had a pelvic osseous bone
metastasis seen on 18F-FDG PET/CT but not on 18F2
PET/CT. 18F2 PET/CT identified bone metastases in 67
of the 115 participants, whereas 18F-FDG PET/CT detected
bone metastases in 38 of the 115 participants. A typical
example in Figure 1, of a 74-y-old man with recently di-
agnosed prostate cancer, shows extensive pelvic osseous
metastases seen on the 18F2 and combined PET scans but
not on 18F-FDG PET. However, 18F-FDG PET/CT detected
extraosseous malignant lesions in 48 of the 115 partici-
pants. Figure 2 illustrates extensive extraosseous metastases
seen on the 18F-FDG and combined scans in a 45-y-old
woman with breast cancer. The most common extraskeletal
sites of metastases were lymph nodes (28/115 participants),
lungs (14/115 participants), and liver (8/115 partici-
pants). 18F2/18F-FDG PET/CT missed three 18F-FDG–
avid lung nodules in 2 participants and two 18F2-avid
skull lesions in another 2 participants. These 4 partici-
pants had other sites of disease that were clearly identi-
fied on both the individual tracer scans and the combined
scans; thus, the missed lesions would not have affected
the overall staging.
Evaluation of 18F2/18F-FDG PET/CT Versus
18F2 PET/CT
Two skull lesions seen on 18F2 scans were missed on the
corresponding 18F2/18F-FDG combined scans. These
missed lesions did not change the participants’ manage-
ment, because other skeletal lesions were identified and
altered the staging accordingly. The 2 missed skull
lesions are presented in Figure 3.
TABLE 2
Clinical Data of Participants for Whom 18F2 PET/CT and Combined 18F2/18F-FDG PET/CT Resulted in More Lesions
Detected Than Did 18F-FDG PET/CT
Characteristic
18F2/18F-PET/CT showed more lesions
than 18F2 PET/CT


































Data are numbers of patients.
178 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 54 • No. 2 • February 2013
by on April 22, 2016. For personal use only. jnm.snmjournals.org Downloaded from 
Evaluation of 18F2/18F-FDG PET/CT Versus
18F-FDG PET/CT
Visual analysis showed that 18F2/18F-FDG PET images
allow for accurate interpretation of uptake in the soft tis-
sues. However, small pulmonary nodules were missed in 2
participants. These nodules, less visible on the combined
scan than on the 18F-FDG scan, are shown in Figure 4.
Evaluation of 18F2 PET/CT Versus 18F-FDG PET/CT
In 19 participants, skeletal metastases were more exten-
sive on 18F2 PET/CT and combined 18F2/18F-FDG PET/CT
than on 18F-FDG PET/CT. When CT data were analyzed
alone, bone metastases were identified in 17 patients, fewer
lesions than on the PET data were seen in 1 patient, and
findings were negative despite lesions seen on PET in 1
patient. In 29 participants, 18F2 PET/CT showed osseous
metastases not present on 18F-FDG PET/CT. In this sub-
group, CT alone identified bone metastases in 15 patients,
whereas fewer lesions than on the PET data were seen in 8
patients and CTwas negative despite lesions seen on PET in
6 patients. The extent of osseous metastases was similar in
another 18 patients on all 3 scans. In 1 participant, 18F-FDG
PET/CT showed focal radiopharmaceutical uptake in a lytic
skeletal metastasis not identified prospectively on 18F2
PET/CT. In retrospect, a rim of increased 18F2 uptake was
noted around this lesion. The remaining 47 (of 115 total)
patients had no osseous metastases identified on any of the 3
scans.
DISCUSSION
Published data support the use of bone imaging (99mTc-
MDP or 18F2) and 18F-FDG PET/CT for detection of skeletal
FIGURE 1. A 74-y-old man with metastatic
prostate cancer. (A–C) Extensive pelvic os-
seous metastases (arrows) are not identified
on 18F-FDG PET scan (A) but are clearly
seen on 18F2 (B) and combined PET (C)
scans. (D) CT demonstrates sclerotic changes.
FIGURE 2. A 45-y-old woman with meta-
static breast cancer. Extensive soft-tissue
metastases (arrowheads) are seen on 18F-
FDG (A) and combined PET (C) scans. A
single bone metastasis (arrow) is visualized
on all 3 scans.
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metastases in selected cancer patients, as both lytic and scle-
rotic lesions may coexist and have different mechanisms of
radiotracer uptake. The spatial resolution of 99mTc-MDP pla-
nar scintigraphy and SPECT affects their sensitivity for de-
tection of osseous metastases. Thus, the transition to the
better resolution of PET/CT for detection of osseous metas-
tases appears appealing, with 18F2 as the radiotracer of
choice. 18F2 PET/CT is superior to 99mTc-MDP planar
scintigraphy and SPECT for bone lesion detection (17–20).
Semiquantitative analysis based on 18F2 PET/CT is also
more accurate than 99mTc-MDP SPECT for assessing the
response to treatment of bone metastases (21).
18F-FDG PET/CT provides unique information on the
glucose metabolism of certain skeletal lesions (22). The
location of a metastasis in the skeleton and the aggressive-
ness of the tumor itself are important with regard to the
extent of the metabolic response induced and therefore the
amount of 18F-FDG uptake (23). Published data suggest
that 18F-FDG PET is less sensitive than bone scintigraphy
for prostate cancer in the detection of osseous metastatic
lesions but may be useful in the detection of metastatic
nodal and soft-tissue disease (24,25). Other investigators
have shown that the level of 18F-FDG uptake in prostate
cancer lesions is an independent prognostic factor and pro-
vides complementary prognostic information to 99mTc-
MDP bone scans (26).
The use of both 18F2 PET/CT and 18F-FDG PET/CT may
be needed in patients with selected cancers. In this study we
combined 2 separate scans into a single imaging procedure,
providing evidence of the superiority of this approach,
which may be cost-effective and convenient for selected
cancer patients. Before the advent of combined PET/CT
technology, Hoegerle et al. reported the use of combined
18F2/18F-FDG administration for PET (27). Indeed, the
authors attempted to use skeletal 18F2 uptake as a surrogate
for anatomic localization of abnormal 18F-FDG in the ab-
sence of fused PET and CT. In their study, the images
obtained after combined administration were not compared
with separate 18F2 and 18F-FDG scans in every participant.
With the availability of PET/CT, an entirely new combined
radiotracer approach allows for a strategy for patient man-
agement not previously possible.
Skull lesions seen on 18F2 PET and subcentimeter-sized
lung nodules seen on 18F-FDG PET were missed on the
combined scan in 4 participants. One missed skull lesion
was from a combined scan acquired at 213 min after in-
jection of 170.2 MBq (4.6 mCi) of 18F2 and 488.4 MBq
(13.2 mCi) of 18F-FDG. Therefore it is conceivable that the
delayed time to imaging may have contributed to the non-
visualization. The proximity to the rib cage of the lung
nodules less visible on the combined scan than on the sep-
arate 18F-FDG scan and the 18F2 uptake in the osseous
structures may have contributed to this lack of clear iden-
tification. However, none of these missed lesions changed
the participants’ management, because other lesions were
identified. We anticipate that future research optimizing the
ratio of 18F2 to 18F-FDG dosages in the combined scan may
solve the infrequent issue of less well visualized lesions on
the combined scan than on the separate scans. In fact, re-
cent data suggest that a ratio of 1:5 may be optimal when
18F2 and 18F-FDG are administered for the cocktail ap-
proach (27). We are also exploring image reconstruction
strategies that will minimize the chance of such missed
lesions on the combined scan.
We acknowledge that some of the lesions that were
identified on the combined scans due to the addition of 18F2
may represent treatment-related changes (i.e., bone repair)
and not active metastases, as our patient population in-
cluded patients already treated. However, additional lesions
were also found in patients presenting for initial staging.
Although this may represent a limitation of the study, our
FIGURE 3. Skull lesions
(arrows) are identified in 2 parti-
cipants on CT (A) and 18F2 PET
(B) scans but not on combined
18F2 scans (C).
FIGURE 4. A 53-y-old woman with soft-
tissue sarcoma. Lung nodule (arrowheads)
is seen on CT (A) and 18F-FDG PET (B)
scans but is not easily identifiable on com-
bined 18F2/18F-FDG scans (C).
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goal was to demonstrate that 18F2/18F-FDG PET/CT shows
promising results, not to document the performance of CT
or separate 18F-FDG PET or 18F2 PET for detection of true-
positive malignant lesions. Therefore, we did not assess the
identified lesions as true-positive, true-negative, false-positive,
or false-negative at the central-site reading. This issue will be
further evaluated in future research.
Other limitations of this study included the participants’
heterogeneous cancer types, the selection bias toward
patients with known malignancy, and the different disease
stages of the participants. To come to statistically sound
conclusions regarding the appropriate indications for
18F2/18F-FDG PET/CT, further prospective enrollment of
subjects is needed, focusing on particular cancer groups.
Furthermore, bone marrow–stimulating therapy induces in-
tense 18F-FDG uptake in the skeleton (29) and may play
a confounding role in the evaluation of osseous structures
on 18F2/18F-FDG PET. This particular instance of evalua-
tion of response to therapy by 18F2/18F-FDG PET/CT also
needs to be separately evaluated in future studies. Another
limitation of the study is that semiquantitative analysis of
the radiopharmaceutical uptake such as standarized up-
take value measurements was not performed. Semiquan-
titative analysis of 18F2 PET/CT scans is still an evolving
field that has no standardized procedures and lacks vali-
dation (8). Issues such as the effect of 18F2 on bone and
soft-tissue uptake of 18F-FDG when given simultaneously
also have not been explored. An analysis of these issues
was beyond the scope of the current study. Although this
kind of analysis should certainly be addressed in future
evaluations, the conclusions on the feasibility of com-
bined 18F2/18F-FDG scans drawn from this study remain
valid. The limitations and issues identified in this trial, as
well as potential solutions to investigate them, are listed in
Table 3.
With regard to radiation exposure, 99mTc-MDP bone scin-
tigraphy results in approximately 4.2 mSv (420 mrem) and
18F-FDG PET/CT in approximately 26.5 mSv (2,650 mrem)
(1.1 mSv/MBq [110 mrem/mCi] from 18F-FDG and 10 mSv
[1,000 mrem] from low-dose CT), or a total of 30.7mSv (3,070
mrem). Combining 18F2 PET/CT and 18F-FDG PET/CT in
a single examination will result in a total of 31.5 mSv (3,150
mrem) (1.1 mSv/MBq [110 mrem/mCi] from 18F-FDG, 1.0
mSv/MBq [100 mrem/mCi] from 18F2, and 10.0 mSv [1,000
mrem] from low-dose CT). Using these estimates and the range
and average of injected doses, the participants in the study
received 10.67–20.35 mSv (1,067–2,035 mrem) (average,
15.18–2.75 mSv [1,518 6 275 mrem]) from the separate
18F-FDG scans, 3.90–13.60 mSv (390–1,360 mrem) (average,
6.90–2.60 mSv [690 6 260 mrem]) from the separate 18F2
scans, and 4.84–19.69mSv (484–1,969mrem) (average, 13.316
2.64 mSv [1,331 6 264 mrem]) from 18F-FDG and 3.70–
14.00 mSv (370–1,400 mrem) (average, 15.186 2.75 mSv
[1,5186 275 mrem]) from 18F2 in the combined scans. The
newest PET/CT scanners have increased sensitivity, and the
doses of 18F-FDG and 18F2 can be reduced further (30), result-
TABLE 3
Limitations and Issues Identified in this Trial, as Well as Potential Solutions to Investigate Them
Issue Potential solution
Ratio of 18F2 and 18F-FDG dosages Conduct dose modeling or phantom studies to determine optimal ratio
of 18F2 to 18F-FDG for combined scan
Sensitivity and specificity of 18F2/18F-FDG PET/CT Conduct prospective trials with pathology or follow-up evaluation of
detected lesions
Quantitation of radiotracer uptake Conduct experiments to determine influence of 18F2 uptake on 18F-FDG
maximum standardized uptake value and vice versa
Interpretation of follow-up studies Conduct prospective studies to evaluate feasibility or usefulness of
18F2/18F-FDG PET/CT in posttherapy setting
18F2 nonspecific uptake Analyze CT data to increase specificity
TABLE 4
Cost Estimates for Separate 99mTc-MDP Bone Scan and 18F-FDG PET/CT vs. Combined 18F2/18F-FDG PET/CT Scan
99mTc-MDP bone scan 18F-FDG PET/CT 18F2/18F-FDG PET/CT
Technical reimbursement: $275 Technical reimbursement: $1,421 Technical reimbursement: $1,421
Professional reimbursement: $48 Professional reimbursement: $140 Professional reimbursement: $140
99mTc-MDP: $100 18F-FDG: $250 18F-FDG: $250
Total: $423 Total: $1,811 18F2: $150
Total: $2,234 Total: $1,961
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ing in less radiation exposure from 18F2/18F-FDG PET/CT.
Thus, instead of patients having to get a separate 99mTc-MDP
bone scan or 18F-FDG PET/CT study, usually on different
days, our strategy allows for a single combined PET/CT scan
with potentially more utility, lower radiation dose, and greater
patient convenience. The recent introduction of hybrid PET/
MR technology in clinical practice (31–33) may lead to the use
of the combined approach with PET/MR scanners in specific
indications, resulting in even less radiation exposure.
Using the current reimbursement rate from the Centers
for Medicare and Medicaid Services, we estimate that
approximately $273 in reimbursement may be saved per
patient by performing 18F2/18F-FDG PET/CT instead of
separate 18F-FDG PET/CT and 99mTc-MDP bone scintigra-
phy. Not everyone referred for these imaging procedures
will be a candidate for the combined scan. However, con-
sidering that approximately 2 million 99mTc-MDP bone
scans are performed annually to evaluate malignancy in
the United States, and assuming that approximately
500,000 18F-FDG PET/CT scans are performed in the same
population, the combined scan can potentially amount to
a total of approximately $136.5 million saved annually in
reimbursement (Table 4). Therefore, this strategy may allow
for potentially significant cost savings for the health-care
system. Although these estimates may be representative of
the health-care costs in the United States, the actual savings
in the health-care systems of the other participating centers is
unknown.
CONCLUSION
This prospective multicenter trial indicated promising
results for 18F2/18F-FDG PET/CT when compared with
separate 18F2 PET/CT and 18F-FDG PET/CT in the evalu-
ation of cancer patients. This finding opens the possibility
for improved patient care and reduction of health-care
costs. Further evaluation of this proposed imaging modality
is warranted to identify the most suitable scenarios for rou-
tine clinical use.
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